Lakefront Biotherapeutics NV (LKFT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lakefront Biotherapeutics NV (LKFT) has a cash flow conversion efficiency ratio of -0.025x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-82.75 Million) by net assets ($3.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View LKFT share price today for real-time trading data and today's change.
Lakefront Biotherapeutics NV - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Lakefront Biotherapeutics NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Lakefront Biotherapeutics NV (LKFT) market capitalisation for the company's overall valuation and market capitalisation.
Lakefront Biotherapeutics NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lakefront Biotherapeutics NV ranked by their cash flow conversion efficiency. Also see how large is Lakefront Biotherapeutics NV's balance sheet for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tibet Mineral Development Co Ltd
SHE:000762
|
0.009x |
|
Guangdong No2 Hydropower Engineering Co Ltd
SHE:002060
|
0.053x |
|
Syngene International Limited
NSE:SYNGENE
|
-0.010x |
|
Costamare Inc
NYSE:CMRE
|
0.044x |
|
ADAMA Ltd
SHE:000553
|
0.036x |
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
-0.127x |
|
Yankershop Food Co Ltd
SHE:002847
|
0.153x |
|
Veridis Environment Ltd
TA:VRDS
|
0.028x |
Annual Cash Flow Conversion Efficiency for Lakefront Biotherapeutics NV (2022–2025)
The table below shows the annual cash flow conversion efficiency of Lakefront Biotherapeutics NV from 2022 to 2025. Review LKFT financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.24 Billion | $-257.46 Million | -0.080x | +27.98% |
| 2024-12-31 | $2.90 Billion | $-320.03 Million | -0.110x | +23.93% |
| 2023-12-31 | $2.80 Billion | $-405.97 Million | -0.145x | +26.71% |
| 2022-12-31 | $2.53 Billion | $-500.54 Million | -0.198x | -- |
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more